Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
University of California, Davis
Takeda
Eli Lilly and Company
University of Arkansas
Hoffmann-La Roche
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Formation Biologics
Nektar Therapeutics
Hoffmann-La Roche
NGM Biopharmaceuticals, Inc
Numab Therapeutics AG
M.D. Anderson Cancer Center
Alume Biosciences, Inc.
Hutchmed
GeoVax, Inc.
Intensity Therapeutics, Inc.
University of Washington
Atara Biotherapeutics
M.D. Anderson Cancer Center
GlaxoSmithKline
NantCell, Inc.
Turning Point Therapeutics, Inc.
NextCure, Inc.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Medical University of Vienna
CytomX Therapeutics
Washington University School of Medicine
SecuraBio
Cullinan Therapeutics Inc.
Genmab
Genmab
Atos Medical AB
Genmab
Baylor College of Medicine
Genmab
University of Washington
Sensei Biotherapeutics, Inc.
Advaxis, Inc.
BioMimetix JV, LLC
Nektar Therapeutics
Ludwig Institute for Cancer Research
Privo Technologies
Incyte Corporation
The University of Texas Health Science Center at San Antonio